BR112020007751A2 - proteínas de ligação de alk7 e usos das mesmas - Google Patents

proteínas de ligação de alk7 e usos das mesmas Download PDF

Info

Publication number
BR112020007751A2
BR112020007751A2 BR112020007751-8A BR112020007751A BR112020007751A2 BR 112020007751 A2 BR112020007751 A2 BR 112020007751A2 BR 112020007751 A BR112020007751 A BR 112020007751A BR 112020007751 A2 BR112020007751 A2 BR 112020007751A2
Authority
BR
Brazil
Prior art keywords
seq
amino acid
alk7
acid sequence
sequence
Prior art date
Application number
BR112020007751-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ravindra Kumar
Roselyne Castonguay
Dianne Sako
Jonathan Belk
Nathan J. SHARKEY
Original Assignee
Acceleron Pharma Inc.
Adimab, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc., Adimab, Llc filed Critical Acceleron Pharma Inc.
Publication of BR112020007751A2 publication Critical patent/BR112020007751A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112020007751-8A 2017-10-25 2018-10-25 proteínas de ligação de alk7 e usos das mesmas BR112020007751A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577038P 2017-10-25 2017-10-25
US62/577,038 2017-10-25
PCT/US2018/057482 WO2019084249A1 (en) 2017-10-25 2018-10-25 ALK7 BINDING PROTEINS AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR112020007751A2 true BR112020007751A2 (pt) 2020-10-20

Family

ID=66246796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020007751-8A BR112020007751A2 (pt) 2017-10-25 2018-10-25 proteínas de ligação de alk7 e usos das mesmas

Country Status (9)

Country Link
US (2) US11981738B2 (https=)
EP (1) EP3700571A4 (https=)
JP (2) JP7433222B2 (https=)
KR (1) KR20200089666A (https=)
CN (1) CN111836642A (https=)
AU (1) AU2018354295B2 (https=)
BR (1) BR112020007751A2 (https=)
CA (1) CA3079963A1 (https=)
WO (1) WO2019084249A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
BR112020007751A2 (pt) 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas
JP7617036B2 (ja) * 2019-05-30 2025-01-17 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合タンパク質及びその使用
JP7541709B2 (ja) * 2020-03-19 2024-08-29 株式会社CUBICStars タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
CN1163599C (zh) 1997-06-06 2004-08-25 Asat应用科学技术股份公司 抗gpiib/iiia重组抗体
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
WO2010065954A2 (en) 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Sparc binding peptides and uses thereof
MX2016007212A (es) 2013-12-19 2016-09-07 Arsanis Biosciences Gmbh Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Ｒｎａ에 특이적으로 결합하는 항체
WO2017177013A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
BR112020007751A2 (pt) 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas

Also Published As

Publication number Publication date
AU2018354295A1 (en) 2020-04-30
US20200392233A1 (en) 2020-12-17
WO2019084249A1 (en) 2019-05-02
US20240287196A1 (en) 2024-08-29
JP7433222B2 (ja) 2024-02-19
JP2024023278A (ja) 2024-02-21
CA3079963A1 (en) 2019-05-02
US11981738B2 (en) 2024-05-14
CN111836642A (zh) 2020-10-27
EP3700571A1 (en) 2020-09-02
EP3700571A4 (en) 2021-07-28
JP2021500895A (ja) 2021-01-14
AU2018354295B2 (en) 2025-08-14
KR20200089666A (ko) 2020-07-27

Similar Documents

Publication Publication Date Title
US20240287196A1 (en) ALK7 Binding Proteins and Uses Thereof
CN113939318A (zh) 抗体-药物缀合物的制剂
US11708414B2 (en) ALK7 binding proteins and uses thereof
KR101453462B1 (ko) Her2에 특이적으로 결합하는 항체
TW200902552A (en) Recombinant anti-epidermal growth pactor receptor antibody compositions
KR20170082495A (ko) 암 치료용 항-ck8 항체
US12365736B2 (en) ALK7 binding proteins and uses thereof
KR20230109853A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
KR20260051471A (ko) Alk7 결합 단백질 및 이의 용도
HK40094995A (zh) Alk7结合蛋白及其用途
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: ADIMAB, LLC (US) ; ACCELERON PHARMA INC. (US)

B25A Requested transfer of rights approved

Owner name: ACCELERON PHARMA INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]